Drug intelligence / Profile preview

coblopasvir + sofosbuvir

Development stage: Unknown
Lead developer: Sunshine Lake Pharma
Modality: Small Molecules
Administration: Oral

Overview

Coblopasvir + sofosbuvir is an oral, fixed-dose combination of two direct-acting antiviral agents for the treatment of chronic hepatitis C virus (HCV) infection. **Coblopasvir** is an NS5A inhibitor, and **sofosbuvir** is a nucleotide analog NS5B polymerase inhibitor; both target essential steps in the HCV replication cycle. This combination is used to achieve sustained virologic response (SVR), considered a cure for HCV. Coblopasvir + sofosbuvir is developed for broad HCV genotype coverage, and has been evaluated in phase 3 trials, particularly for genotypes prevalent in Asia-Pacific regions.

Targets

NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)

Beyond the preview

Go deeper on coblopasvir + sofosbuvir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on coblopasvir + sofosbuvir.

Explore the full profile